

Supporting information for:

The structural analysis of the angucycline-like antibiotic auricin from *Streptomyces lavendulae* subsp. *lavendulae* CCM 3239 revealed its high similarity to griseusins

Maria Matulova^{1#}, Lubomira Feckova^{2#}, Renata Novakova², Erik Mingyar², Dominika Csolleiova², Martina Zdiriencikova¹, Jan Sedlak³, Vladimir Patoprsty¹, Vlasta Sasinkova¹, Iveta Uhliarikova¹, Beatrica Sevcikova², Bronislava Rezuchova², Dagmar Homerova², Jan Kormanec^{2*}

¹ Institute of Chemistry, Slovak Academy of Sciences, 845 38 Bratislava, Slovak Republic; e-mail@e-mail.com

² Institute of Molecular Biology, Slovak Academy of Sciences, 845 51 Bratislava, Slovak Republic; maria.matulova@savba.sk

³ Cancer Research Institute BMC, Slovak Academy of Sciences, 845 05 Bratislava, Slovak Republic; jan.sedlak@savba.sk

These authors contributed equally to this work

* Correspondence: jan.kormanec@savba.sk; Tel.: +421259307419 (J.K.)

Table of Contents

Figure S1. ^1H NMR spectrum of auricin (1) in CDCl_3 at 25°C	3
Figure S2. ^1H - ^1H COSY spectrum of 1 in CDCl_3 at 25°C	3
Figure S3. ^1H - ^1H TOCSY spectrum of 1 in CDCl_3 at 25°C	4
Figure S4. Selective 1D TOCSY spectrum of 1 in CDCl_3 at 25°C	4
Figure S5. ^{13}C NMR spectrum of 1 in CDCl_3 at 25°C	5
Figure S6. ^1H - ^{13}C HSQC spectrum of 1 in CDCl_3 at 25°C	5
Figure S7. ^1H - ^{13}C H2BC spectrum of 1 in CDCl_3 at 25°C	6
Figure S8. ^1H - ^{13}C HMBC spectrum of 1 in CDCl_3 at 25°C . Detail 1.....	6
Figure S9. ^1H - ^{13}C HMBC spectrum of 1 in CDCl_3 at 25°C . Detail 2.....	7
Figure S10. ^1H - ^{13}C HMBC spectrum of 1 in CDCl_3 at 25°C . Detail 3.....	7
Figure S11. ^1H - ^{13}C HMBC spectrum of 1 in CDCl_3 at 25°C . Detail 4.....	8
Figure S12. ^1H - ^1H NOESY spectrum of 1 in CDCl_3 at 25°C	8
Figure S13. Selective 1D NOESY spectrum of 1 in CDCl_3 at 25°C	9
Figure S14. The most important correlations of 1	9
Table S1. ^1H and ^{13}C NMR data of 1	10
Table S2. Comparison of ^1H and ^{13}C NMR data for 1 , 2 and 3	11
Figure S15. 3D structure of 1	12
Figure S16. ATR Infrared spectrum of 1	12
Table S3. Characteristic FTIR bands identified in the spectrum of 1	13
Figure S17. Analysis of conversion of 1 to methoxyauricin.....	14
Figure S18. Genetic organisation of the auricin (1) <i>aur1</i> cluster	15
Figure S19. Comparison of auricin KS α (Aur1D) with griseusin KS α (Gris-ORF1) and several representative KS α proteins from main groups of aromatic polyketides.....	16
Figure S20. Comparison of auricin KS β (Aur1E) with griseusin KS β (Gris-ORF2) and several representative KS β proteins from main groups of aromatic polyketides.....	19
Figure S21. Comparison of auricin CYC Aur1C with griseusin partial CYC.....	22
Figure S22. Comparison of auricin oxygenase Aur1C with griseusin partial oxygenase.....	22




Figure S1. ^1H NMR spectrum of auricin (**1**) in CDCl_3 at 25°C .




Figure S2. ^1H - ^1H homocorrelated COSY spectrum of **1** in CDCl_3 at 25°C .




Figure S3. ^1H - ^1H homocorrelated TOCSY spectrum (80 ms mixing time) of **1** in CDCl_3 at 25°C .




Figure S4. 1D TOCSY spectrum of **1** in CDCl_3 at 25°C after selective irradiation of D-forosamine H-6' at a 120 ms mixing time.




Figure S5. ¹³C NMR spectrum of **1** in CDCl₃ at 25°C.




Figure S6. ¹H-¹³C hetero-correlated HSQC spectrum of **1** in CDCl₃ at 25°C.




Figure S7. ^1H - ^{13}C two bond heterocorrelated H2BC spectrum of **1** in CDCl_3 at 25°C .




Figure S8. A selected detailed region of the ^1H - ^{13}C multiple bond correlation HMBC spectrum of **1** in CDCl_3 at 25°C .




Figure S9. A selected detailed region of the ^1H - ^{13}C multiple bond correlation HMBC spectrum of **1** in CDCl_3 at 25°C .




Figure S10. A selected detailed region of the ^1H - ^{13}C multiple bond correlation HMBC spectrum of **1** (in CDCl_3 at 25°C), optimised for a long range coupling constant $^nJ_{\text{H,C}}$ 10Hz. Signals marked with ovals are the most important for the aglycone structure determination.




Figure S11. A selected detailed region of the ^1H - ^{13}C multiple bond correlation HMBC spectrum of **1** (in CDCl_3 at 25°C) optimised for a long range coupling constant $^nJ_{\text{H,C}}$ 8Hz. Signals marked with ovals are the most important for the aglycone structure determination.




Figure S12. NOESY spectrum of **1** in CDCl_3 at 25°C , (mixing time 300ms).




Figure S13. NMR spectra of **1** in CDCl_3 at 25°C . A – ^1H NMR spectrum of **2**, B and C - 1D NOESY spectrum of **1** after selective irradiation of the anomeric signal H-1' and the H-5' signal, respectively, both issued from D-forosamine molecule (mixing time 250ms).




Figure S14. The most important correlations of **1**: COSY (bold lines), selected HMBC (blue arrows) and selected NOESY (red arrows).

Table S1 ^1H and ^{13}C NMR data (600MHz, CDCl_3 , 25°C) for auricin (**1**).

Pos.	δ_c	type	δ_H (ppm) J (Hz)	COSY	ROESY/NOESY/ 1	H2BC ²	HMBC ³			
							S	M	W	VW
1	173.75, CO									
2	37.39, CH ₂	(a) 2.884 (5.2, 18.1, 1H, dd) (b) 2.727 (18.1, 1H, d)	H3			C3	C1 C1,C3,C4	C12	C3,C4 C4a	C5
3	71.31, CH	5.351 ⁴ (1H, dd)	H2, H4 ⁴	H2a,b		C2,C4		C1, C4		
4	68.45, CH	5.360 ⁴ (1H, d)	H3 ⁴	H3'b		C3		C4a,C10a		C5
4a	138.05, qC									
5	181.45, qC									
5a	131.06, qC									
6	119.59, CH	7.692 ⁴ (1H)				C7	C8	C5a,C9a	C5,C9	
7	137.29, CH	7.683 ⁴ (1H)				C6, C8	C5a,C9a,C9	C8,C5		C10
8	125.70, CH	7.361 (4.6, 5.2, 1H, dd)				C7	C5a,C6,C9a,C9	C10		C5
9	162.27, qC									
9a	114.92, qC									
10	186.55, qC									
10a	140.68, qC									
11	98.91, qC									
12	80.85, CH	5.382 (1H, s)		H1', H5', H14, H15			C1',C12	C10a,C13		C14
13	202.26, CO									
14	48.88, CH ₂	(a) 2.645 (10.7, 13.9, 1H, dd) (b) 2.604 (3.3, 13.9, 1H, dd)	H15	H16 H15		C15	C13,C15,C16 C11,C13		C11 C15	C12 C12,C16
15	69.28, CH	4.562 (3.3, 6.4, 10.5 1H, m)	H14, H15	H14b, H16		C14, C16	C12,C14,C16			
16	21.55, CH ₃	1.353 (6.4, 3H, d)	H15	H14a, H15		C15	C14,C15	C13	C12	
OH-9	-	12.00 (1H, s)					C8,C9,C9a		C7	C10
1'	95.94, CH	4.854 (3.0, 1H, d)	H2'a,b	H2'a,b; H12		C2'		C11		C5'
2'	29.40, CH ₂	(a) 2.041 (1H, m) (b) 1.661 (1H, m)	H1'; H3'a,b	H1', H3'a,b H1'		ⁱⁿ	ⁱⁿ			
3'	14.70, CH ₂	(a) 1.576 (1H, m) (b) 1.274 (1H, m)	H2'a,b; H4'	H2'a,b; H4' H2'a, H4', H5', H7'		ⁱⁿ	ⁱⁿ			
4'	64.62, CH	2.08 (1H, m)	H5'	H3'a,b; H5', H6'		ⁱⁿ	ⁱⁿ			
5'	68.30, CH	3.111 (1H, m)	H4', H6'	H3'b, H6', H7'		C6'	ⁱⁿ			
6'	17.74, CH ₃	0.792 (6.2, 3H, d)	H5'	H4', H5', H7'		C5'	ⁱⁿ			
7'	39.91, CH ₃	1.835 (6H, s)		H3'b, H5', H6'		ⁱⁿ	ⁱⁿ			

¹ – H-H interaction via dipolar couplings (through space), ² – double bond H-C-C interaction through ²J_{H,C} scalar couplings, ³ – long range H-C interaction via ³J_{H,C} scalar couplings (through bond); types qC, CH, CH₂, CH₃ mean quaternary, tertiary, secondary and primary carbons, respectively; s - singlet, d- doublet, dd – doublet of doublet, t – triplet, m – multiplet; ⁴ – overlapped, ⁱⁿ – not assigned. In HMBC column: cross peaks show C-H long range interactions with corresponding proton in the same line; intensity of cross peak signals S-strong, M – medium, W – weak, VW - very weak. (a),(b) – resolved geminal protons of CH₂ group.

Table S2. Comparison of ^1H and ^{13}C NMR data for auricin (**1**) (600 MHz, CDCl_3 , 25°C) with data of equivalent positions in 3'-O- α -D-forosaminyl-(+)-griseusin A (**2**) [15] and 4'-dehydro-deacetylgriseusin A (**3**) [17].

Auricin (2) (600 MHz, CDCl_3)			3'-O- α -D-forosaminyl-(+)-griseusin A (2) (500 MHz, CDCl_3)			4'-dehydro-deacetylgriseusin A (3) (500 MHz, CDCl_3)		
Pos.	δ_{C} , type	δ_{H} (J in Hz)	Pos.	δ_{C} , type	δ_{H} (J in Hz)	Pos.	δ_{C} , type	δ_{H} (J in Hz)
1	173.75, CO	-	2	173.8, CO	-	12	173.1, CO	-
2	37.39, CH_2	2.884, dd (5.2, 18.1) 2.727, d (18.1)	3	37.1, CH_2	2.98, dd (4.6, 17.1) 2.71, d (17.1)	11	36.0, CH_2	2.94, dd (4.9, 17.8) 2.67, d (17.8)
3	71.31, CH	5.351, dd ^b	3a	65.7, CH	4.72, dd (2.4, 4.3)	10	66.7, CH	4.68, dd (3.0, 4.8)
4	68.45, CH	5.36, d ^b	11b	68.2, CH	5.26, d (2.7)	9	68.1, CH	5.27, d (3.0)
4a	138.05, qC	-	11a	138.2, qC	-	8a	138.5, qC	-
5	181.45, qC	-	11	181.8, qC	-	8	181.7, qC	-
5a	131.06, qC	-	10a	131, qC	-	7a	131.2, qC	-
6	119.59, CH	7.692 ^b	10	119.8, CH	7.68, dd (1.8, 7.9)	7	119.7, CH	7.65, m
7	137.29, CH	7.683 ^b	9	137.1, CH	7.65, t (7.9)	6	137.2, CH	7.65, m
8	125.7, CH	7.361, dd (4.6, 5.2)	8	125.6, CH	7.32, dd (1.8, 7.9)	5	125.5, CH	7.30, m
9	162.27, qC	-	7	162.3, qC	-	4	162.2, qC	-
9a	114.92, qC	-	6a	115.3, qC	-	3a	115.2, qC	-
10	186.55, qC	-	6	187.2, qC	-	3	187.3, qC	-
10a	140.68, qC	-	5a	143.7, qC	-	2a	140.5, qC	-
11	98.91, qC	-	5, 2'	96.1, qC	-	2	99.4, qC	-
12	80.85, CH	5.382, s	3'	69.7, CH	4.90, d (3.6)	3'	75.9, CH	5.47, d (8.6)
13	202.26, CO	-	4'	64.6, CH	5.59, q (3.6)	4'	203.0, CO	-
			4' (-OAc)	21.1, CH_3	2.08, s			
			4' (-OAc)	170.4, CO	-			
14	48.88, CH_2	2.645, dd (10.7, 13.9) 2.604, dd (3.3, 13.9)	5'	36.0, CH_2	1.91, m	5'	47.6, CH_2	2.57, m
15	69.28, CH	4.562, m (3.3, 6.4, 10.5)	6'	63.0, CH	4.37, m	6'	69.5, CH	4.21, m
16	21.55, CH_3	1.353, d (6.4)	7'	20.6, CH_3	1.24, d (6.4)	7'	21.4, CH_3	1.39, d (6.2)
OH-9	-	12.00, s				OH-4	-	11.9, s
1'	95.94, CH	4.854, d (3.0)	1''	93.7, CH	4.82, s			
2'	29.4, CH_2	2.041, 1.661, m	2''	29.7, CH_2	1.47, 1.61, m			
3'	14.7, CH_2	1.576, 1.274, m	3''	13.6, CH_2	1.47, m			
4'	64.62, CH	2.08, m	4''	65.7, CH	1.95, m			
5'	68.3, CH	3.111, m	5''	68.0, CH	3.19, d (6.4, 9.8)			
6'	17.74, CH_3	0.792, d (6.2)	6''	18.2, CH_3	0.58, d (6.4)			
7'	39.91, CH_3	1.835, s	4''-N-(CH_3) ₂	40.3, CH_3	1.92, s			

Types qC, CH, CH_2 , CH_3 mean quaternary, tertiary, secondary and primary carbons, respectively. CO – carbonyl, s – singlet, d – doublet, t – triplet, dd – doublet of doublet, ^b – overlapped. Highlighted yellow positions show significantly different values.




Figure S15. Three dimensional structure of **1**. It has resulted from MM2 force field for minimum energy calculation in Chem3D Pro program.




Figure S16. FT-IR ATR Infrared spectrum of **1**.

Table S3 Characteristic FTIR bands identified in the spectrum of **1**. The signals were assigned based on Miller and Willis, 1969.

wavenumber (cm ⁻¹)	assignment
2957	ν_{as} (C-H) of CH ₃
2925	ν_{as} (C-H) of CH ₂
2895	ν (C-H) of CH
2873	ν_{s} (C-H) of CH ₃
2851	ν_{as} (C-H) of CH ₂
2784	ν (O-H) chelation of OH-9 with C-10 carbonyl
1794	ν (C=O) of ketone C-13
1737	ν (C=O) of ester (ring A)
1670	ν (C=O) of ketone C-5
1652	ν (C=O) of ketone C-10
1623	ν (C=C) arom.
1577	ν (C=C) arom.
1517	ν (C=C) arom.
1456	δ (C-H)
1385	δ (C-H)
1283	δ (O-H) phenolic
1244	ν (C-O) of ester (ring A)
1234	ν (C-N) of terc.amine
1201	ν (C-O-C) of cyclic ether (ring B) ³ C-O- ¹² C
1183	ν (C-O-C) of cyclic ether (ring E) ¹⁵ C-O- ¹² C
1148	ν (C-O-C) of glycosidic ¹¹ C-O- ¹⁷ C
1133	ν (C-N) of terc.amine
1082	ν (C-O-C) of ether ¹⁷ C-O- ⁵⁷ C

ν - stretching vibrations, δ - deformation vibrations, ⁿC stands for carbon in position n

References

Miller, R. G. J. & Willis, H. A. *Irscot: Infrared structural correlation tables and data cards*. Irscot System – Tables 1-9. Heyden & Son Ltd., London, 1969




Fig. S17. (a) HPLC analysis of conversion of compound **1** to methoxyauricin in the presence of methanol (methanolysis), and catalysed by silica. 24 μg of purified compound **1** was dissolved in 120 μl methanol and incubated in room T with and without silica. At the time point indicated, 10 μl of the sample was analysed by analytical HPLC as described previously [7,9]. Traces show the elution of metabolites monitored at 245 nm (y -axis) versus time (x -axis). **(b)** High resolution ESI MS spectra of compound **1** and methoxyauricin and ESI MS/MS fragmentation of compound **1** and methoxyauricin to give the D-forosamine $m/z = 142.2$ $\{M+H\}^+$ signal. **(c)** Scheme of conversion of compound **1** to methoxyauricin.




Figure S18. Genetic organisation of the auricin (1) *aurI* cluster and its adjacent regions. Each thick arrow denotes the direction of expression and the size of the gene. Details of individual genes and their products are provided in Genbank Acc. No. KJ396772. Bent arrows indicate the position and direction of promoters regulated by auricin-specific regulators [5,8,9].

```

Gra-ORF1 -----VTRRVVITGVGVRAPGG
Qin-ORF19 -----MTRRVVITGIGVRAPGG
Med-ORF1 -----MTRRVVVTGLGVRAPGG
ActI-ORF1 VPLDAAPVDPASRGPVSAFEPSSSHGADDDDDHRTNASKELFGLKRRVVITGVGVRAPGG
AlnL -----VNRSVAITGIGVVAPGG
FrnL -----VNRQVAVTGIGVVAPGG
AlpA -----LSRRRVVITGIEVIAPGG
JadA -----VTARRVVITGIEVLAPGG
LanA -----MGRRVVVTGIGVLAPGG
PgaA -----VSRRRVVITGVGV LAPGG
UrdA -----VSGAHSRRVVITGIGV TAPGG
SimA1 -----VRRRVVITGVGV MAPGG
Aur1D -----MTRRVVITGIGV LAPGG
Gris-ORF1 -----VERRAVITGIGV CAPGG
ElmK -----MTG--RQVVITGIGVRAPGG
TcmK -----MTRHAEKRVVITGIGVRAPGG
PdmA -----VSRPQGGGPRRVAITGMGV VAPGG
MtmP -----MNRRVVITGIGV VAPGA
Dau-ORFA -----VNRRVVITGMGV VAPGA
DpsA -----VNRRIVITGIGV VAPGA
OxyA -----MSKIHDARRVVITGIGV VAPGD
: .: ** : * ***

```

```

Gra-ORF1 SGTKEFWDLLTAGRTATRPISFFDASPFRSRIAGEIDF DAVAEGFSPREVRRMDRATQFA
Qin-ORF19 SGTKEFWDLLTAGRTATRRISFFDAAAFRSQVAAEADFFPEAEGFSPREIRRMDRATQFA
Med-ORF1 SGARQFWDLLSSGRTATRSITSF DASA CRSQVAGEIDFDPVAEGLSPREIRRMDRAAQFA
ActI-ORF1 NGTRQFWELLTSGRTATRRISFFDPSPYRSQVAAEADFD PVAEGFGPRELDRMDRASQFA
AlnL VGKKAFWDLLVSGRTATRTISFFDPSPFRSQVAAEVD FDPQRSGLSPREARRLDRAAQFA
FrnL IGRKPYWEQLTSGRTATRAISFFDASPFRSRIAAEVD FDPAAAGLSPREVRRMDRAAQFA
AlpA VGRENFWNLLSSGRTATRGITFFDPAPFRSRVAAEAD FDFPAHGLSPQEVRRLDRAAQFA
JadA TGSKAFWNLLSEGR TATRGITFFDPTPF RSRVAAEIDFDP EAHGLSPQEIRRMDRAAQFA
LanA IGAENFWSLLSEGR TATRGITFFDPSSFRSQIAAEAD FDAERSGLSPQEIRRMDRAAQFG
PgaA IGAKNFWSLLSEGR TATRGITFFDPSSFRSRVAAEAD FDEPMHGLTPQEIRRMDRAAQFA
UrdA VGSKNFWSLLSDGR TATRRISFFDPSPFRSQVAAEAD FDAELLGLSPQEIRRMDRAAQFA
SimA1 IGVKNFWSLLSEGR TATRGITFFDPAPFRSRVAAEID FFFPEKHGLGPQKIRRMDRAAQLA
Aur1D IGTAFWNLLSSGRTATRGITLFDPAF RSRVAAEVD FHPERHGLTSLEVRMDRAAQFG
Gris-ORF1 TGVD SFWELMCDGR TATRGITLFDPSPYRSRVAAEID FDPRAHGLTPQEIRRMDRAAQFG
ElmK TGVKAFWDL LSSGRTATRRISFFDPSPYRSQIAAEID FDDLGE GFTDRQIARWDRAVLLA
TcmK AGTAAFWDL LTAGRTATRTISLFDAAPYRSRIAGEID FDPIGEGLSPRQASTYDRATQLA
PdmA SGRKAFWNLLTDGR TATRKISLFDPA GFRSRIAAECDF DPAAEGLTPREVRRMDRAAQLA
MtmP VGVEAFWEQLTAGR TATRTISLFDASA FRSRIAAEVD FDAARHGFGPAEAERLDRATQFA
Dau-ORFA IGIKSFWELL SGT TATRAITTFDATPF RSRVAAECDF DPVAAGLSAEQARRLDRAQQFA
DpsA VGTKPFWELL SGT TATRAITTFDATPF RSRVAAECDF DPVAAGLSAEQARRLDRAQQFA
OxyA VGTKPFWEMLTAGR TATRPISFFDASPFRSQVAAECDF DPAAEGLSQRQVRAWDR TMQFA
* :*. : * **** *: **: **:*. * * . *: : **: :.

```

```

Gra-ORF1 VACTRDALADSGLD TGALDPSRIGVALGS AVASATSLENEYLVMSDS GREWLVDPAHLSP
Qin-ORF19 VACTREAVADSGLEFAGVDPHRVGVSLGS AVASATSLENEYLV MADKGREWLVD PDYLS P
Med-ORF1 VVCSREAVADSGLSFEGVRPERIGVSVGS AVAAAMSLEKEYRVLS DQGREWEVDPTYLTP
ActI-ORF1 VACAREAF AASGLD PD TLD PARVGVSLGS AVAAATSLEREYLL LSDSGRDWEVDAAWLSR
AlnL VVSARECMADSGLEFVELDPHRTGVSVGS AVGGTTGLEREYLV LSDSGRLWEVDS DYVSP
FrnL VVSARESLADSGLDVADLDPHRIGV SIGSAVG GTTSLEREYLA LSDSGRQWELDLSYLS P
AlpA VVASRGAVADSGLDVAALDPHRVGVTVGS AVGATMGLDEEYRVVSDGGRLEAVDHTYAVP
JadA VVAAR- AVADSGIDLA AHD PYRVGVTVGS AVGATMGLDEEYRVVSDGGRLDLVDHAYAVP
LanA VVTAREALADSGLDLQAGLDPYRTGV TIGSAVGATMGLDEEYRVVSDGGRLDLVDHRYTPQ
PgaA VVTAREALADSGLDLAGFDPHRTGV TIGSAVGAT TGLDDEYRVVSDGGRLDLVDHTYAPP
UrdA VVTAREAVADSGLEFASLDPHRTGV TIGSAVGATMGLDQEYRTVSDSGRLDLVDHEYAVP
SimA1 VIATREAVADSGLDLDATDPHRRGVTVGS AVGAT TGLDQEYRVVSDGRLGLVDHRYAPP
Aur1D VVATREALADSGLDLA AFD PYRIGIAMGTGVGAI SGLDTAYRVASDEGRI AQVDHMYAPG
Gris-ORF1 VVTAREAFADSGLDGAALDPFR TGVSLGTAIGAAGGLDAEYRVVSDGRLGLVDHRYATP
ElmK VAAAREALAHSGLAPGALRPETVGVSVGS AVGCTTSLDTEYARVSHGGADWLVDHTLAVQ
TcmK VVCAREALKDSGLDPA AVNPERIGV SIGTAVGCTTGLDREYARVSEGGSRWLVDHTLAVE
PdmA VVSAREALADSGLVAGEGDPARFAVSLGS AVGCTMGLEDEYVVVSDQGRDWLVDHSYGVP
MtmP LVSAREAVADAGLDG- KTDPSRTGVALGS AVGCTTGLDTQYNNVSEGGSDWYVDHTRAVD
Dau-ORFA LVAGQEALTD SGLRIGEDSAHRVGV CVGTAVGCTQKLESEYVALSAGGANWVVDPHRGAP
DpsA LVAGQEALADSGLR IDEDSAHRVGV CVGTAVGCTQKLESEYVALSAGGAHWVVDPGRGSP
OxyA YVAAREALADSGV- TGEADPLRTGVMAGTACGMTMSLDREYAVVSDGRLWQVDDAHGVP
: . . :*: . . : *:. . *: * : * :*

```


Gra-ORF1	AHIYAEVGGYATRSQAYHMTGLKKDGREMAESIRAALDEARLDRTAVDYVNHAHGSGTKQN
Qin-ORF19	AQIYAEVTGYATRCNAYHMTGLKKDGREMAEAI RAALDES RVDPTVV DYVNHAHGSGTKQN
Med-ORF1	ARIYAEVTGYATRLNAHHMTGLKTDGREMAEAIRVALDESRI DPTAIDYVNHAHGSGTKQN
Act I -ORF1	ARIHAEISGYATRCNAYHMTGLKADGREMAETIRVALDESRTDATIDYINAHGSGSTRQN
AlnL	AHVYGVIGGYATRCNAYHMTGLRPDGHEMAEAIRHS LDQARLPDLVDYVNHAHGSGTKQN
FrnL	AHVYALVSGYATRCNAYHMTGLTPHGREMAEAIRHALAESGTDPAAVDYVNHAHGSGTKQN
AlpA	AHIYAEIAGYSTRSNAYHMTGLRPDGAEMAE AIDLALAEARLN PQAIDYVNHAHGSGTKQN
JadA	AHIYAEIAGYATRSNAYHMTGLRPDGAEMAE AIRVALDEARMNPTEIDYINAHGSGTKQN
LanA	AHIYAEIAGYASRCNAFHMTGLRPDGDREMGEA IRVALDEARINPEAIDYINAHGSGTKQN
PgaA	AHIYAEIAGYASRCNAFHMTGLRPGDREMSE AIDVALGEARMNPDRIDYINAHGSGTKQN
UrdA	AHVYAEIAGYATRSNAFHMTGLRPDGREMAEAIRIALDEARLN PEDIDYVNHAHGSGTKQN
SimA1	ARIYAEIGGYASRCNAFHMTGLRPDGREMAEAIRVALDEARLN PEDIDYINAHGSGTKQN
Aur1D	AHVYAEIAGYASRSSAFHMTGLRPDGREMAEAIT VALDEARLD PGDLDYVNHAHGSGTRQN
Gris-ORF1	AYVYAEIAGYASRGNAFHMTGLRSDGAELAAAIRAALDEARLDASAVDYVNHAHGSGTRQN
ElmK	APVLAEVAGFATRANAYHMTGLRSDGREMAAAAIDAALLAAGRGPADV IDYINAHGSGTRQN
TcmK	AHAYA EVRGFATRSNAFHMTGLRKPDGREMAEAITAALDQARRTGDDLHY INAHGSGTRQN
PdmA	AHVYCEVAGYATRGNAYHMTGLKPDGREMAEAIRVMAMDAARVAPADLDY INAHGSGTKQN
MtmP	AHVYAEISGFASRCNAYHMTGLRPDGIEMAE AIRTALDEARLDPTAVDYVNHAHGSGTKQN
Dau-ORFA	ARIYAEIGGYASRGNAYHMTGLRADGAEMAAA ITAALDEARRDP SDVDYVNHAHTGATRQN
DpsA	ARIYAEIGGYASRGNAYHMTGLRADGAEMAAA ITAALDEARRDP SDVDYVNHAHTGATKN
OxyA	ARAYAEIAGYAGRCNAYSMTGLRSDGRELA EAVSRALDIARVP SEVDYVNHAHGSA TKQN
	* : * : * : * : * : * : * : * : * : * : * : * : *

Figure S19. A comparison of auricin KS α (Aur1D) from *S. lavendulae* subsp. *lavendulae* CCM 3239 with griseusin KS α (Gris-ORF1) from *S. griseus* K-63 and several representative KS α proteins from main groups of aromatic polyketides. Protein sequences (and accession numbers) are as follows: granaticin Gra-ORF1 (CAA09653), qinimycin Qin-ORF19 (WP_058047374), medermycin Med-ORF1 (BAC79044), actinorhodin ActI-ORF1 (CAC44200), alnumycin AlnL (ACI88861), frenolicin FrnL (AAC18107), kinamycin AlpA (AAR30152), jadomycin JadA (AAB36562), landomycin LanA (AAD13536), gaudimycin PgaA (AAK57525), urdamycin UrdA (CAA60569), simocyclinone SimA1 (AAK06784), auricin Aur1D (AAX57191), griseusin Gris-ORF1 (CAA54860), elloramycin ElmK (CAP12600), tetracenomycin TcmK (AAA67515), pradimicin PdmA (ABM21747), mithramycin MtmP (CAA61989), daunorubicin Dau-ORF1 (AAA87618), doxorubicin DpsA (AAA65206), oxytetracycline OxyA (AAZ78325).

```

AlpB      -----MTA-----SVVVTGLGVTAPNGLGLKDYWAATLGGKHGIGRIT
JadB      -----MSA-----SVVVTGLGVAAPNGLGREDFWASTLGGKSGIGPLT
UrdB      --VNTGAV-----EVAVTGLGVVAPNGLGTDAYWAATRKGTSIGIARIS
Aur1E     -----MSA-----RILVTGIGVAAPSGLGVEDFWSVTRIGKNAIGPVT
Gris-ORF2 -----VSAPGGG-----DRGRTLITGMGLATPHGVDVEDFWAATRVGKNAIGPVT
LanB      -----MTA-----RVVITGIGIAAPNGFGVEDYWAATRVGKSAIGRIT
PgaB      -----MST-----RTVITGIGVATPNGLGVDEFWAATRVGKNAIARVT
SimA2     -----MTT-----SVVVTGLGVAAPNGLGTADYWAATREGRSGIGRVT
ActI-ORF2 -----MS-----VLITGVGVVAPNGLGLAPYWSAVLDGRHGLGPVT
Qin-ORF18 -----MTSKDG-----LNGRTVITGIGVTAPNGLGTEAFWKAVLAGHTGIGPVT
Med-ORF2  -----MS-----DRALITGIGVVAPNGLGVKEYWNATLEGRGGIAPLT
Gra-ORF2  -----VSTPD-----RRRAVVTGLSVAAPGGLGTERYWKSLLTGENGIAELS
AlnM      -----MTLATP--AAQETPERTGRPTAVITGIGVAAPNGLGTEQWWQSTLQGTSGIGPVV
FrnM      -----MTTAPSR-TAQGAPPGAALP-PVFTGIGVAAPNGLGTEEWAAATLRGEHGLRPVT
ElmL      VTGSDTEDGST-----GWITGLGVVAPNNGIGAEYWKATLEGRSGLRTIT
TcmL      -----MSAPAP-----VVVTGLGIVAPNGTGTEEYWAATLAGKSGIDVIQ
PdmB      -----VAPT-----VVAPTGIGVEEHWAATLRGVVPVIGPLT
MtmK      -----MS-----ADASQAVITGIGVAAPNGLSVKAWWDAVLRGESGIRRLS
OxyB      -----MTGQLAPAPETGTGRPGGSVRPVVTGLGVVAPNGLGTERYWAATLRGDSGIGRIT
Dau-ORFB  -----VVTGLGIVAPNGLGVGAIWDAVLNGRNGIGPLR
DpsB      MTGTAARTASSQLHASPAGRRGLRGRAVVTGLGIVAPNGLGVGAYWDAVLNGRNGIGPLR
          :.: * * . * * : :

```

```

AlpB      RFDPTGYPARLAGQIDGFEADRLLPSRLLPQTDRTVTRL-ALVAADWALADAGADPAQLP-
JadB      RFDPTGYPARLAGEVPGFAAEHLPSRLLPQTDRTMTRL-ALVAADWALADAGVRPEEQD-
UrdB      RFDPSRYPVQLAGEIEGFDAGHLPGRLLPQTDRTMTQL-ALVAADWAFEDA AVRPGDLP-
Aur1E     RFDASAYPSRLAGEIHGFEPKEHLPGRLVPQTDRTVTQL-ALVAADCAFADAGIEPGTID-
Gris-ORF2 RFDASGYPARLAGEIRGFSAADHLPGRLVAQTDRVTQL-ALVAADRAFRDAGVAPGDLP-
LanB      RFDPTQYPARLAGEIRGFDARDHLPGRLIPQTDRTMTQL-ALVATDSAFEDAGVKPGDIP-
PgaB      HFDPSYPARLAGEIRGFEAKDHLPSRLIPQTDRTMTQL-ALVAADCAFEDAGVELGNIP-
SimA2     RFDPSQYPSRLAGEVPGFVAEDHLPSRLLPQTDHMTL-ALVSADWALQDAGIRPEELP-
ActI-ORF2 RFDVSRYPATLAGQIDDFHAPDHIPGRLLPQTDTPSTRL-ALTAADWALQDAKADPES---
Qin-ORF18 RFDASRYAASLAGQIDDFDAAEHLNSRLLPQTDTPSTRL-ALVAADWALTDADVSPDT---
Med-ORF2  RFDASRYPSRLAGQILGFDPAEHLPNRLLPQTDVSTRL-ALVAAEQALADGGVDPAE---
Gra-ORF2  RFDASRYPSRLAGQIDDFEASEHLPSRLLPQTDVSTRY-ALAAADWALADAGVGPES---
AlnM      DYDASRYPSRLVGRIDGFEAAEHLPGRLLPQTDRTVTRL-ALVAGAEALADADANPAE---
FrnM      EYDASGHPGGLVGRVPDFDAARHLPGRLLPQTDRTVTRL-ALVAADEALKDAAVDPAE---
ElmL      GFDAGQYPVRVAGEVGTFADEPSLSGRILPQTDRTMTRY-ALVASDWALADSGVRTDEHDG
TcmL      RFDPHGYPVRVGEVLAFDAAAHLPGRLLPQTDRTMTQH-ALVAAEWALADAGLEPEKQDE
PdmB      RFDASRYPSPPGGEVPGFDAAERVPGRLLIPQTDHWTLL-ALAAATDLALADAGVVPaelPE
MtmK      RFDPGRYPARLAGEIRDFVDADHVPGRLLPQTDRTVTRL-SLAVAREAVEDAGVDLERLP-
OxyB      RFDPSGYTSSLAGEIADF-DPARLPNRLLPQTDLMTRL-ALVAAEEALDDAGADPRTMP-
Dau-ORFB  RFADDGRLGRLAGEVSDFVPEDHLPKRLLVQTDPMQMTALAAAEWALREAGCAPSS---
DpsB      RFTGDGRLGRLAGEVSDFVPEDHLPKRLLAQTDPMQY-ALAAAEWALRESGCSPPS---
          : . * . : * : * : * : * : * :

```

```

AlpB      -----EFDMGVITASAGGFEEFGQELQALWSQGSQYVSAYQSFawFYAVNSGQISI
JadB      -----DFDMGVVTASAGGFEEFGQELQKLWSQGSQYVSAYQSFawFYAVNSGQISI
UrdB      -----EFEMGVITASAGGFEEFGQRELQALWSRGSRYVSAYQSFawFYAVNSGQISI
Aur1E     -----PYAMGVVTAAGAGGFEEFAENELRKLWSEGAKHVSAYQSFawFYAVNSGQISI
Gris-ORF2 -----ANGMGVVTAAGSGGFEEGERELRKLWSLGANHVSAYQSFawFPTANTGQIAI
LanB      -----EYDMGVVTASTAGGFEEFGQNELQALWSKGSQHVSAYQSFawFYAVNSGQISI
PgaB      -----AYDMGVVTASTSGGFEEFGQNELKKLWSQGSRYVSAYQSFawFYAVNSGQISI
SimA2     -----EYAAGVVTAAGGFEEFGQNELRALWSKGSQYVSAYQSFawFYAVNTGQISI
ActI-ORF2 -LT-----DYDMGVVTANACGGFDFTHREFRKLWSEGPkSVSVYESFAWfyAVNTGQISI
Qin-ORF18 -LP-----DYDMGVVTSNAGGFDFTHREFDKLWNKGPDFVSVYESFAWfyAVNTGQISI
Med-ORF2  -LV-----DFDLGVITSNAGGFAFTHREFANLWSKGPEYVSVEYFAWfyAVNTGQVSI
Gra-ORF2  GLD-----DYDLGVVTSTAQGGFDFTHREFHKLWSQGPAYVSVYESFAWfyAVNTGQISI
AlnM      LAEQDGYGEYCGGVVTSNATGGFEFTHREIRKLWTQGPQQVSVYESFAWfyAVNTGQLSI
FrnM      LP-----EYGASAVTSNATGGFEFTHREIRKLWTEGPARVSVYESFAWfyAVNTGQISI
ElmL      -----FSTGVITASAGGFEEFGQRELQKLWGS GPGEVSAYQSFawFYAVNTGQISI
TcmL      -----YGLGVLTAAAGAGGFEEFGQREMQLWGTGPERSAYQSFawFYAVNTGQISI
PdmB      -----YEMAVVTASSSGGVEFGQREIQALWRDGP RHVGAYQSIawFYAATTGQISI
MtmK      -----RYAAGVSTASSAGGFEEFGQRELQALWSKGGQYVSAYQSFawFYAVNTGQISI
OxyB      -----DFAAGVVTAASAGGFDFGQRELEALWSKGAHVSAWfyFPVNSGQISI
Dau-ORFB  -----PLEAGVITASAGGFASGQRELQNLWSKGAHVSAWfyAVNTGQIAI
DpsB      -----PLEAGVITASAGGFAGQRELQNLWSKGAHVSAWfyAVNTGQIAI
          .. * : ** . * : * * * * . * . * : * : * :

```

AlpB RNMKGPGAGVVVSEAGGLDAVAQARRQIRKG-TSLIVTGAVDASLCPWGWVAQLAGGRL
 JadB RNMKGPGSGVVVSDQAGGLDAVAQARRQIRKG-TRLIVSGGVDASLCPWGWVAHVASDRL
 UrdB RNMGRGPSGVVSDQAGGLDAVAQARRQIRKG-TRLVMSGAVDASICPWGWVAMASNRL
 Aur1E RNGLRGPGAGVVISDQAGGLDALAQARRQLRKG-SKLIATGGFDAPICSLGWASHLHGGLM
 Gris-ORF2 RSDSRGPNGVVVDQAGGLDALGQARRLIRRG-TGLVAAGGFEASLTPLGWTARLSTGLM
 LanB RNMGRGHSVVVSDQAGGLDAIAQARRQIRKG-SKLICSGGVDASICPWGWVAQLANGRV
 PgaB RNMKGPGSGVVVSDHAGGLDAIAQARRQIRKG-SKLIFSGGFDASICPWGWAAQIAGGRL
 SimA2 RHGLRGPSGVVSDQAGGLDALAQARRQIRRG-SQVIVSGGIDASICSWGWAQILTSGRM
 ActI-ORF2 RHGMRGPSSALVAEQAGGLDALGHARRTIRRG-TPLVVSGGVDSDLPWGWVSQIASGRI
 Qin-ORF18 RHKLRGPSAALVGEQAGGLDAAHAARLLRKGTNLNTALTGGCEASLCPWGLVAQIPSGFL
 Med-ORF2 RHNVRGPGAALVAEQAGGLDALGHARRSLRLG-TPLVVTGGVDSALDPWGWASHLSSGLI
 Gra-ORF2 RNTMRGPSAALVGEQAGGLDAIGHARRTVRRG-PGWCSAVASTRRSTRGASSSQLSGGLV
 AlnM RHKLRGPSGVLVSEQAGGLDAIQSRRTLRQG-VKLSLTGGMDSSLDPWGLVSHLASGRL
 FrnM RHGMRGPGAGVVADQAGGLDALGQARRVLRKG-GVLAVSGGVESALDPWGLAAHASSGTL
 ElmL RHGLRGHSSVVAEQAGGLDAVAQATRLVDHGTLRVAVAGGFEAPVSPWGLVAQIPSGLL
 TcmL RHGMRGHSSVFVTEQAGGLDAAHAARLLRKGTNLNTALTGGCEASLCPWGLVAQIPSGFL
 PdmB RHGMRGPCGVVVAEQAGALESFAQARRYLADG-ARVVVSGGTDAPFSPYGLTCQLGSGRL
 MtmK GYDLRGPSGVLVTEQAGGLDAVAQARRLLRRG-SELMVTGGVDSALCPWGWTAHLAGGRL
 OxyB RHDMRGPGGALVAEQAGGLDAVAKARRHVRDG-TPLMLTGGVDGSLCPWGWLCMTRSGAL
 Dau-ORFB RHDLRGPVGVVVAEQAGGLDALAHARRKVRGG-AELIVSGAMDSLCPYGMAAQVRSGRRL
 DpsB RHDLRGPVGVVVAEQAGGLDALAHARRKVRGG-AELIVSGAVDSSLCPYGMAAQVKSGRL
 : * . . : : * * . : : : * : * : :

AlpB STSDEPDHAYLPFDRDARGFVPGEGGAILIAEDAAAARTRGAR-PYGEIAGYGATIDPRP
 JadB STSEEPARGYLPFDREAQGHVPGEGGAILVMEAAEAARERGAR-IYGEIAGYGSTFDPRP
 UrdB STSRDPERAYLPFDAAAGGHVPGEGGALLVLEELEQARARGARQIYGVIAGYGSTLDPRP
 Aur1E STSDEPERAYLPFDAAAGYVPGEGGAMLILEDSDARDRGARTVYGEFAGYGATLDPKP
 Gris-ORF2 STSDDPDRAYLPFHFAARGYVPGEGGALLILEDERSALARGAATAHAELAGYSATLDPRP
 LanB STSENTERAYLPFDADASGYVPGEGGALLILEDAEAARQRGAEENVYGEIAGYGSTFDPRP
 PgaB SHSDRPERAYLPFDRAANGYVPGEGGALLILEDERTARERGAEKIYGEVAGYGSTFDPRP
 SimA2 STDDDPATAYRPFDAAGHVPGEAGALLVLEEAGAAAARGAR-VYGRIAGYGTTFDPKP
 ActI-ORF2 STATDPDRAYLPFDERAAGYVPGEGGAILVLEDSAAAEARGRHDAYGELAGCASTFDPAP
 Qin-ORF18 TTATDPARAYLPFSADASGYVPGEGGAILVAEDEASARERGVQQVYGELAGYAATFDPAP
 Med-ORF2 SDSDDPDRAYLPFDARARGHVPGEAGAFVMEDEQCALRRGAGQVYGELAGYAATFDPHP
 Gra-ORF2 STVADPERAYLPFDVDASGYVPGEGGAVLIVEDADSARARGAERIY--VRSPLRRDPAP
 AlnM SRSDDPATAYLPFDTRAAGQVPGEGGAMLVLEETAARARGA-RVYGEIAGYAATFSPRP
 FrnM SRSGDPATAYLPFDRRALGTVVGEAGALLTLETPRHAERDAPRIYGELAGYAATFDPAP
 ElmL STVADPARAYLPFDPDASGWVPGEGGAALVVERAADARARGADHVGRIAGHASTFDPRP
 TcmL SEATDPHDAYLPFDARAAGYVPGEGGAMLVAEARADSARERDAATVYGRIAGHASTFDARP
 PdmB STGADPARAYLPFDAAANGFVPGEGGAILIEQAATAQDR---SYGRIAGYAATFDPDP
 MtmK STGDDPARAYLPFSADADGEVVGEGGALLVLERAAAAPSRGA-RVYGVFAGYAATFDPDP
 OxyB TTRTDPRRAYLPFSPDASGYVPGEGGALLVLEDPRAAAERGAPQVYGRIAGYAATFDPRP
 Dau-ORFB SGSDDPDTAGYLPFDRRAAGHVPGEAGAILAVEDAERVAERGGK-VYGSIAGT-ASFDPDP
 DpsB SGSDNPTAGYLPFDRRAAGHVPGEAGAILTVEDAERAAERGA-K-VYGSIAGYGASFDPDP
 : . . * * * * * * * * * * . * :

AlpB GSGREPGLRKAIETALADARLSAADIDVVVFADGAGDPAGDRIEADAI STVFGDRGVPVTV
 JadB GSGREPGLRKAIELALADAGAAPGDIDVVVFADAAAAPELDRVEAEALNAVFGTGAVPVTA
 UrdB GSGRPAGLRKAIELALADAGAAPPEIDVVVFADAAAAPELDRIEAEALTQVFGARAVPVTA
 Aur1E GSGREPGLRRIDVALTDAACHPAEVDVVVFADGAATPRLDREEAEAITAVFGPRAVPVTV
 Gris-ORF2 GSGREPGLRRAIELALADAGVAPAEVDVVVFADAAAGSPEPDAVEVAAGVFGPRAVPVTA
 LanB GSGREPGLRRAIELALADADAEPDIDGVVFADAAAGTPELDRVEAEALIEVFAGAGVPVTA
 PgaB GSDREPGLRHAIEVALADAGVTAADVDDVVVFADAAAGSPDLDRQEADAITAVFGPSGVPVTA
 SimA2 GSGREPGLRRAIELALTDAGLAPADIDVVVFADAAAAPDLDRIEARALVEVFGPRGLPVTA
 ActI-ORF2 GSGRPAGLERAIRLALNDAGTGPEIDVVVFADGAGVPELDAEAEARAI GRVFGREGVPVTV
 Qin-ORF18 GTGRPPALRRAAEALADAGLAPGDIDVVVFADGAGVPELDAEAEAAI SGLFGAGAVPVTA
 Med-ORF2 DSGRPPALRRAAELAIADAGLEPSDIDGVVFADAAAGSADLDRTEAEAAIAAVFGPRGVPVAA
 Gra-ORF2 GSGRPPALGRAAEALALAEAGLTPADISVVVFADGAGVPELDRAEADTLARLFGPRGVPVTA
 AlnM GSGRPPGLERARLALADAGLVEDVDVVVFADAAAGLPTADDEEAAALRALFGPYGVPVTA
 FrnM GSGRPPGLERARLALADAGLAPGDVDVVVFADAAAGLPAADAAEAAALRALFGPGGVPVSV
 ElmL GLGRPPALARAVRTALDRARHPGDIDVVVFADAAAGLPEQDAAEVAALTEVFGSRKVPVTA
 TcmL GTGRPTGPARRAIRLALAEARVAPEDVDVVYADAAAGVPALDRAEAEALAEVFGPGAVPVTA
 PdmB GSGRPPTLERAVRAALDDARLTPADVDDVVVFADAAAGVPDLDRAEADAIGAVFGPRGVPVTA
 MtmK GRGGTPQLARAAELALVDAGMTPDQVDVVVFADAAAGERAADRAEADALTRVFGARGVPVTA
 OxyB GSGREPGLRRALRLALDDAGIGPADVDVVVFADAMGVPALDAVETQVLAAEFGRGVPVTA
 Dau-ORFB GSGRPSALARAVETALADAGLDRSDIAVVVFADGAAGVGLDVAEAEALASVFGPHRVPVTV
 DpsB GSGRPSALARAVETALADAGLDGSDIAVVVFADGAAGVPELDAEAEALASVFGPRRVPVTV
 . . . : * * : : : * * * * * . * * . : * * : * * :

AlpB	PKTMTGRLYSGGAPLDLAAAFALALRDGVIPPTVHID-PCADYPLDLVLGEPR-PAPLRTA
JadB	PKTMTGRLYSGAAPLDLAAAFAMRDGVPPSVGVS-PSPDHDLDLVHHQER-AMTVRSA
UrdB	PKTMTGRLYSGAAPLDLAAAFAMRDGVPPSVGVS-PSPDHDLDLVHHQER-AMTVRSA
Aur1E	PKTMTGRINSGGAPIDVVSASVLSMREGLIPPTTNVE-LSDAYDLDLVAVRPR-TASVRTA
Gris-ORF2	PKTMIGRLQAGGAPVDVVTAVLAIREGLIPPTADAE-SATARELDLVVGRPR-TASVGTA
LanB	PKTMTGRLYSGAAPVDVVTAVLAMREGLIPPTNVNS-LSPEYDIDLVTAGPR-TARVRNA
PgaB	PKTMIGRLYSGAAPVDVVAAVLAIREGLIPPTTNVE-LSPDYDLDLVTGQPR-TASVRTA
SimA2	PKSMTGRLNSGAGSLDVATALLAIRDGVIPPTINVT-AQDDYELDLVTAGAR-SARLRSA
ActI-ORF2	PKTTTGRLYSGGGPLDVVTALMSLREGVIAPTAGVTSVPREYGIDLVLGEPR-STAPRTA
Qin-ORF18	PKALTGRLYSGGGPLDVATALLSIRDGVIPPTPTGAPVPEDYGLDLVQGAPR-DQAVRTA
Med-ORF2	PKALTGRLLAGGGPLDVVAASVRLRDGLLPAVPYEGETPDAYGIDLVRGTPR-PTSARAA
Gra-ORF2	PKALTGRLLCAGGGPADLAAALLALRDQVI PATGRHRAVPDAYALDLVTGRPR-EAALSAA
AlnM	PKTLTGRLFGGGAPLDVAAALLALRDGVIPPTAGIDRPVPEHRLDLVRGTPR-HTPLRTA
FrnM	PKTQTGRLASGGPALDVAAALLALRDGLVPPAVHLDEVDPAYGLDLVRDTPR-ALPLRTA
ElmL	PKTMTGRLYSGGGALDTATALLALRDGVVPPPTVGTRTAPP--ELDLVLGAPR-DLPLRNA
TcmL	PKTMTGRLYAGGAALDVATALLSIRDGVVPPPTVGTPGAPAPGLGIDLVLHQPR-ELRVDTA
PdmB	PKSLTGRLYAGGPALDAATALLAMHDSVIPPTAGGADVPPGYALDLVGAEPR-PARLRTA
MtmK	PKTMTGRLLSAGGASLDLAAALLALRDQVVPPTVNVTEPADDCPVDLVTGRPR-PLPLRAA
OxyB	PKTMTGRLLAGGASLDLAAALLSLRDQVVPPTVHVDGGEIPDSLVLVTGAPR-PARLRHA
Dau-ORFB	PKTLTGRLYSGAGPLDVATGLLALRDEVVPATGHVH-PDPDLPLDVVTGRPRAMADARAA
DpsB	PKTLTGRLYSGAGPLDVATALLALRDEVVPATAHVD-PDPDLPLDVVTGRPRSLADARAA
	** : ** : . * . . * . . : : : : . . . : * : * * *

AlpB	LILARGHGGFNSAMAVRAV-----
JadB	LVIARGHGGFNSAMVVRSA-----
UrdB	LVIARGHGGFNSAVVVRVAVG-----
Aur1E	LVLARGRGGFNSAVVVRVAVD-----
Gris-ORF2	LVLARGHGGFNSAVVLRVAVD-----
LanB	LVVARGYGGFNSAMVVRGTDR-----
PgaB	LVLARGVGGFNSAVVVRVAVD-----
SimA2	LVVARGHGGFNSALVVQDAA-----
ActI-ORF2	LVLARGRWGFNSAAVLRRFAPTP----
Qin-ORF18	LVLARGRHGFNSAVVVRVRA-----
Med-ORF2	LVLARGRWGFNSAVVVKAADRG-----
Gra-ORF2	LVLARGRHGFNSAVVVTLRGSDDRPT
AlnM	LVLARGHGGFNAAVVVR---APEAA--
FrnM	LVLARGHGGFNAAVVVRGRRRPRTA--
ElmL	LVLARGTGGFNSAVVVRVAVD-----
TcmL	LVVARGMGGFNSALVVRRHG-----
PdmB	LIIARGYGGFNAAVLVRGPNT-----
MtmK	LVLARGRGGFNAAVVVRALS-----
OxyB	LVLARGHGGFNSAMVVSGRD-----
Dau-ORFB	LVVARGHGGFNSALVVRGAA-----
DpsB	LLVARGYGGFNSALVVRGAA-----
	* : : *** ** : * . :

Figure S20. A comparison of auricin KS β (Aur1E) from *S. lavendulae* subsp. *lavendulae* CCM 3239 with the griseusin KS β (Gris-ORF2) from *S. griseus* K-63 and several representative KS β proteins from main groups of aromatic polyketides. Protein sequences (and accession numbers) are as follows: kinamycin AlpB (AAR30151), jadomycin JadB (AAB36563), urdamycin UrdB (CAA60570), auricin Aur1E (AAX57192), griseusin Gris-ORF2 (CAA54859), landomycin LanB (AAD13537), gaudimycin PgaB (AAK57526), simocyclinone SimA2 (AAK06785), actinorhodin ActI-ORF2 (CAC44201), qinimycin Qin-ORF18 (WP_058047373), medermycin Med-ORF2 (BAC79045), granaticin Gra-ORF2 (CAA09654), alnumycin AlnM (ACI88862), frenolicin FrnM (AAC18108), elloramycin ElmL (CAP12601), tetracenomycin TcmL (AAA67516), pradimicin PdmB (ABM21748), mithramycin MtmK (CAA61990), oxytetracycline OxyB (AAZ78326), daunorubicin Dau-ORFB (AAA87619), doxorubicin DpsB (AAA65207).

```

Gris-ORFX      ---IQNSRNDPRFVQISHELKPFIEPYDPETWRTPADAMATRFYDWSAGE
Aur1C          GQRIQESRTDPRFMRI SHDLLPFIQPYDPATWRTPADAMATRFYDWSASE
                **:*.****;:***:*  **:****  *****.*****.**

```

Figure S21. A comparison of auricin CYC Aur1C (AAX57190) from *S. lavendulae subsp. lavendulae* CCM 3239 with the griseusin partial CYC (Gris-ORFX) from *S. griseus* K-63.

```

Gris-ORFY      -VPEDDDARIVVVGAGPVGLLLAGLLRRSGADVVLLEQLTAPTTESRASTLHARTMEILD
Aur1I          MSGDYSETQVI VVGAGPVGLLLAGELRLAGTDVVLDKLTAPTTESRASTLHSRTMEILD
                : .:~::~:***** ** :*:*****:~:*****:*****

Gris-ORFY      GCGVRDRLGAVEREPRGHFGGIGLDLTLPVPRPGQWKVPQTRLEEVLARWARELGVRI--
Aur1I          TRGLLDGLGDI PNDPSGHFGGIPFDLALPGPYPGQWKVAQTRLEEVLGQWAADLGADIRR
                *: * ** : .:* ***** :*:** * *****.*****.:** :*. *

```

Figure S22. A comparison of auricin oxygenase Aur1I (AAX57196) from *S. lavendulae subsp. lavendulae* CCM 3239 with the griseusin partial oxygenase (Gris-ORFY) from *S. griseus* K-63.